Research Study

A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Principal Investigator 
Raewyn Broady

Overview

Body Locations and Systems 
Leukemia
Disorders and Conditions 
ClinicalTrials.gov# 
NCT02913261
Status 
Recruiting
Study Start/End 
Dec 1, 2017 to Jul 9, 2019
Locations 
Vancouver General Hospital
Name/Title 
Larissa Pals, Research Assistant
Phone 
604-875-4111 ext.22967
Purpose of Study 

To evaluate the safety and efficacy of ruxolitinib compared to Best Available Therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.